At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Stifel analyst Paul Matteis lowered the firm’s price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of $231.00. The company’s shares closed yesterday at ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve ...

stating it "significantly undervalues" the company and does not serve shareholders' best interests. Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage ...

(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' ...

Chico now expects that the biotechnology company will post earnings per share of $16.18 for the year, down from their previous forecast of $16.32. The consensus estimate for Biogen’s current ...

Chico now forecasts that the biotechnology company will post earnings per share of $3.15 for the quarter, down from their previous forecast of $3.29. The consensus estimate for Biogen’s current ...